Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases

• Váldodahkkit: Aishwarya Mary Johnson (Dahkki), Robert Barigye (Dahkki), Hariharan Saminathan (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2021-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel coronavirus disease 2019 (COVID-19) pandemic that lacks globally accessible effective antivirals or extensively available vaccines. Numerous clinical trials are exploring the applicability of repurpo...